Imeglimin

 Imeglimin is an experimental drug being developed as an oral anti-diabetic.[1] It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis, increase muscle glucose uptake, and restore normal insulin secretion. It will be the first of a new class of anti-diabetic if it is approved.

Imeglimin
Imeglimin.svg
Names
Preferred IUPAC name
(2S)-N6,N6,2-Trimethyl-1,2-dihydro-1,3,5-triazine-4,6-diamine
Identifiers
CAS Number
  • 775351-65-0
3D model (JSmol)
  • Interactive image
ChemSpider
  • 26232690
PubChem CID
  • 24812808
UNII
  • UU226QGU97
CompTox Dashboard (EPA)
  • DTXSID50228237 Edit this at Wikidata
InChI
  • InChI=1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1
    Key: GFICWFZTBXUVIG-SCSAIBSYSA-N
  • InChI=1/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1
    Key: GFICWFZTBXUVIG-SCSAIBSYBC
SMILES
  • C[C@H]1NC(=NC(=N1)N)N(C)C
Properties
Chemical formula
C6H13N5
Molar mass155.205 g·mol−1
Pharmacology
ATC code
None
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

This article uses material from the Wikipedia article
 Metasyntactic variable, which is released under the 
Creative Commons
Attribution-ShareAlike 3.0 Unported License.